ID: ALA237143

Max Phase: Preclinical

Molecular Formula: C13H8N4

Molecular Weight: 220.24

Molecule Type: Small molecule

Representations

Canonical SMILES:  N#Cc1ccc(-c2nc3cccnc3[nH]2)cc1

Standard InChI:  InChI=1S/C13H8N4/c14-8-9-3-5-10(6-4-9)12-16-11-2-1-7-15-13(11)17-12/h1-7H,(H,15,16,17)

Standard InChI Key:  SBEHOQVAOUNCSL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 220.24

Molecular Weight (Monoisotopic): 220.0749

AlogP: 2.50

#Rotatable Bonds: 1

Polar Surface Area: 65.36

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.33

CX Basic pKa: 2.13

CX LogP: 2.29

CX LogD: 2.29

Aromatic Rings: 3

Heavy Atoms: 17

QED Weighted: 0.68

Np Likeness Score: -1.62

References

1. Bavetsias V, Sun C, Bouloc N, Reynisson J, Workman P, Linardopoulos S, McDonald E..  (2007)  Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.,  17  (23): [PMID:17933533] [10.1016/j.bmcl.2007.09.076]

2. Loddo R, Briguglio I, Corona P, Piras S, Loriga M, Paglietti G, Carta A, Sanna G, Giliberti G, Ibba C, Farci P, La Colla P..  (2014)  Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines.,  84  [PMID:25014745] [10.1016/j.ejmech.2014.07.011]

Source

Source(1):

• Scientific Literature